Do You Need a Repeat Biopsy — Before Starting Immunotherapy?

Not automatically. Most patients starting immunotherapy do not need a brand-new biopsy — if your existing archival tissue sample from an earlier biopsy or surgery is recent enough, large enough, and still representative of your current cancer, it can usually be used for the biomarker tests your eligibility depends on, such as PD-L1 or MSI/MMR testing.

A repeat biopsy is asked for only when the archival sample cannot answer that question — never as a routine formality, and never because your case looks "worse" than someone else's. Knowing which situation applies to you can save you an unnecessary procedure, or help you approach a genuinely needed one with far less anxiety.

This page explains the general reasoning your oncology team uses to make this call. It does not interpret your specific report — any biopsy or biomarker test for CION patients is coordinated at accredited partner pathology labs and imaging centres, and your own oncologist reviews your specific result with you.

General patterns only, indicative as of August 2026 — your pathology lab makes the final call on tissue adequacy for your specific case, and this table does not constitute an eligibility guarantee.

• Tissue block already used up — earlier diagnostic or biomarker tests consumed most or all of the available sample, leaving too little for further testing.
• Sample is old — tissue collected a long time ago, especially years back, may no longer reliably reflect the cancer's current biology.
• Disease has progressed or spread to a new site — a biopsy from the original site may not represent how the cancer looks at a new or growing site today.
• Tissue quality has degraded — poorly preserved or aged FFPE blocks can stain unreliably, giving results a pathologist can't fully trust.
• An earlier result looked inconsistent — if a biomarker result doesn't fit the overall clinical picture, retesting (on the same or new sample) can confirm or correct it.

If none of these apply to your situation, there's a good chance archival tissue is enough — worth asking your oncologist directly which reason, if any, applies to you.

For most patients, no — a repeat biopsy done for biomarker testing carries a generally low level of risk, similar to the biopsy that first diagnosed your cancer. Most repeat biopsies use a thin needle guided by ultrasound or CT imaging rather than open surgery, and the most common after-effects are minor bruising, brief soreness at the site, or a small amount of bleeding that settles without treatment.

Risk does vary by which organ is being sampled. A lung biopsy carries a small chance of a temporary partial lung collapse (pneumothorax), which is usually managed conservatively if it happens; a liver biopsy carries a small bleeding risk that the radiologist screens for beforehand; a lymph-node or skin-accessible biopsy is generally lower risk still. Your specialist will walk through the specific risk for your planned site, and what would count as a reason to seek urgent care afterwards, before you consent to the procedure.

Serious complications are uncommon but not zero — this is general procedure information, not a guarantee for your individual case, and it is not a substitute for the consent conversation with the doctor performing your biopsy.

1. 1

   Discussion and consent

   Your oncologist explains exactly why archival tissue can't be used this time, which site will be sampled, and the specific risks and alternatives, before you're asked to consent.

2. 2

   Choosing the method and site

   A radiologist or surgeon selects the safest, most accessible site that still represents the cancer being tested — often a lymph node, a lung nodule, or a liver lesion under image guidance.

3. 3

   The procedure

   Most repeat biopsies are day-care procedures under local anaesthesia, typically well under an hour, with a short observation period afterwards before you go home.

4. 4

   Pathology processing and results

   The sample is processed at an accredited partner pathology lab, and biomarker results typically take about one to two weeks depending on the specific panel ordered, after which your oncology team reviews them with you.

Reusing an existing sample avoids putting you through an additional procedure, saves the time a new biopsy and its healing period would take, and can reduce the overall cost of the diagnostic workup — a real, practical concern many families weigh alongside the medical one. This is why your pathology lab's first step, before any repeat-biopsy conversation begins, is always to check whether the tissue you already have is enough.

If you're also weighing what the testing itself costs, our page on biomarker testing costs walks through which tests are typically needed and what drives the price, separately from this biopsy decision.

• Genetic and Genomic Reports: Reading the Summary Page — once your sample (archival or new) has been tested, this page helps you make sense of the report that comes back.
• Where to Get Biomarker Testing Done in Hyderabad — where testing is coordinated if a repeat biopsy or fresh panel is needed.
• Can Biomarker Testing Be Repeated on a Newer Sample? — the related question of retesting biomarkers if your disease changes later in treatment.
• Immunotherapy at CION Cancer Clinics — the full picture of how CION supports patients through the immunotherapy decision and journey.

This page explains general repeat-biopsy and archival-tissue terminology for education only and does not interpret any individual patient's report. Biopsy and biomarker testing for CION patients are coordinated at accredited partner pathology labs and imaging centres. Bring your report and biopsy history to a consultation for a doctor's assessment of what applies to you.

Thousands of families have asked this exact question

One more procedure can feel like one more hurdle. Our oncologists check your existing tissue first, every time, so you're never asked to go through a biopsy that wasn't necessary.